Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

NCT01430572 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Advanced Cancers
Solid Tumors

Interventions

DRUG: Pazopanib
DRUG: Everolimus

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]